Sanoski Cynthia A, Bauman Jerry L
Department of Pharmacy Practice and Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
Chest. 2002 Jan;121(1):19-23. doi: 10.1378/chest.121.1.19.
The interaction between amiodarone and warfarin has only been described in patients being followed up for relatively short time periods. The objectives of this study were to characterize the interaction between these two agents in a clinical situation over a longer period of time in a larger cohort of patients, and to determine the relationship between the maintenance dose of amiodarone and the resultant need to adjust the dose of warfarin.
This was an observational trial of a cohort of patients receiving a stable warfarin regimen in whom oral amiodarone was initiated. Patients received both amiodarone and warfarin for at least 1 year, and the dosage of warfarin was adjusted as clinically necessary to achieve an international normalized ratio of 2 to 3. Data from a total of 43 patients were analyzed.
At baseline, prior to initiation of amiodarone, the warfarin dose was 5.2 +/- 2.6 mg/d. The magnitude of the interaction between these two agents peaked at 7 weeks, which resulted in a 44% mean maximum reduction in the warfarin dose. The warfarin dose inversely correlated with the maintenance dose of amiodarone (r(2) = 0.94, p < 0.005). Minor bleeding episodes occurred in five patients (12%). For patients receiving amiodarone maintenance doses of 400, 300, 200, or 100 mg/d, it is recommended that the daily warfarin dose be reduced by approximately 40%, 35%, 30%, or 25%, respectively.
The magnitude of the amiodarone/warfarin interaction is highly dependent on the maintenance dose of amiodarone. This relationship can aid clinicians in adjusting the dose of warfarin patients receiving long-term amiodarone treatment.
胺碘酮与华法林之间的相互作用仅在随访时间相对较短的患者中得到描述。本研究的目的是在更大规模的患者队列中,在更长的时间内,在临床情况下描述这两种药物之间的相互作用,并确定胺碘酮维持剂量与由此产生的调整华法林剂量需求之间的关系。
这是一项对接受稳定华法林治疗方案并开始口服胺碘酮的患者队列进行的观察性试验。患者同时接受胺碘酮和华法林治疗至少1年,华法林剂量根据临床需要进行调整,以达到国际标准化比值为2至3。共分析了43例患者的数据。
在基线时,即开始使用胺碘酮之前,华法林剂量为5.2±2.6mg/d。这两种药物之间的相互作用强度在第7周达到峰值,导致华法林剂量平均最大降低44%。华法林剂量与胺碘酮维持剂量呈负相关(r² = 0.94,p < 0.005)。5例患者(12%)发生轻微出血事件。对于接受400、300、200或100mg/d胺碘酮维持剂量的患者,建议将华法林每日剂量分别减少约40%、35%、30%或25%。
胺碘酮/华法林相互作用的强度高度依赖于胺碘酮的维持剂量。这种关系有助于临床医生调整接受长期胺碘酮治疗患者的华法林剂量。